{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:01:11Z","timestamp":1775890871541,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ejphar.2023.175837","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T03:08:14Z","timestamp":1686884894000},"page":"175837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss"],"prefix":"10.1016","volume":"954","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3286-4319","authenticated-orcid":false,"given":"Anna","family":"Thors\u00f8 Larsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten A.","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2023.175837_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101282","article-title":"KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats","volume":"53","author":"Andreassen","year":"2021","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejphar.2023.175837_bib3","article-title":"Anti-obesity medications and investigational agents: an obesity medicine association (OMA) clinical practice statement (CPS) 2022","volume":"2","author":"Bays","year":"2022","journal-title":"Obes. Pillars"},{"key":"10.1016\/j.ejphar.2023.175837_bib4","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(21)00944-2","article-title":"Cagrilintide plus semaglutide for obesity management","volume":"397","author":"Becerril","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2023.175837_bib5","doi-asserted-by":"crossref","first-page":"R945","DOI":"10.1152\/ajpregu.00275.2010","article-title":"Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates","volume":"299","author":"Bello","year":"2010","journal-title":"Am. J. Physiol. Integr. Comp. Physiol."},{"key":"10.1016\/j.ejphar.2023.175837_bib6","first-page":"1","article-title":"Semaglutide for the treatment of overweight and obesity: a review","author":"Bergmann","year":"2022","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2023.175837_bib7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ejphar.2023.175837_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4321\/S1889-836X2021000400002","article-title":"Sequential treatment in osteoporosis . New trends","volume":"13","author":"Casado","year":"2021","journal-title":"Rev Osteoporos Metab Miner"},{"key":"10.1016\/j.ejphar.2023.175837_bib9","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.2147\/DDDT.S365416","article-title":"Clinical insight on semaglutide for chronic weight management in adults: patient selection and special considerations","volume":"16","author":"Chao","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejphar.2023.175837_bib10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis","volume":"32","author":"Cosman","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ejphar.2023.175837_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2023.175837_bib14","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/dom.14280","article-title":"The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity","volume":"23","author":"Friedrichsen","year":"2021","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2023.175837_bib15","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1152\/ajpendo.00419.2016","article-title":"Optimization of tolerability and efficacy of dual amylin and calcitonin receptor agonist, KBP-089, through dose escalation and combination with a GLP-1 analogue","volume":"313","author":"Gydesen","year":"2017","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2023.175837_bib16","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bph.13723","article-title":"A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference","volume":"174","author":"Gydesen","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.175837_bib17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejphar.2015.05.051","article-title":"KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration","volume":"762","author":"Hjuler","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.175837_bib18","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/oby.21563","article-title":"The dual amylin- and calcitonin-receptor agonist KBP-042 increases insulin sensitivity and induces weight loss in rats with obesity","volume":"24","author":"Hjuler","year":"2016","journal-title":"Obesity"},{"key":"10.1016\/j.ejphar.2023.175837_bib19","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejphar.2023.175837_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.175837_bib21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1463-1326.2012.01557.x","article-title":"Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight","volume":"14","author":"Jelsing","year":"2012","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2023.175837_bib22","series-title":"Preclinical Weight Loss Efficacy of AM833 in Combination with Semaglutide in Rodent Models of Obesity","first-page":"P01","article-title":"Preclinical weight loss efficacy of AM833 in combination with semaglutide in rodent models of obesity","author":"John","year":"2021"},{"key":"10.1016\/j.ejphar.2023.175837_bib23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejphar.2023.175837_bib24","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.1c00565","article-title":"Development of cagrilintide, a long-acting amylin analogue","author":"Kruse","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.175837_bib25","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2147\/DDDT.S58459","article-title":"Liraglutide and obesity: a review of the data so far","volume":"9","author":"Ladenheim","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejphar.2023.175837_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-020-00678-2","article-title":"The Dual Amylin and Calcitonin Receptor Agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile","volume":"21","author":"Larsen","year":"2021","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.ejphar.2023.175837_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biopha.2022.113842","article-title":"Does receptor balance matter ? \u2013 Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models","volume":"156","author":"Larsen","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2023.175837_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1124\/jpet.119.257576","article-title":"The dual amylin and calcitonin receptor agonist KBP-088 induces weight loss and improves insulin sensitivity superior to chronic amylin therapy","volume":"370","author":"Larsen","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2023.175837_bib29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/jpet.119.263392","article-title":"The calcitonin receptor plays a major role in glucose regulation as a function of dual amylin and calcitonin receptor agonist therapy","volume":"374","author":"Larsen","year":"2020","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2023.175837_bib30","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre , randomised , dose-finding phase 2 trial","volume":"6736","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2023.175837_bib31","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3803\/EnM.2021.970","article-title":"Operationalizing treat-to-target for osteoporosis","volume":"36","author":"Lewiecki","year":"2021","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2023.175837_bib32","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1038\/s41598-019-44591-8","article-title":"Combined Amylin\/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss","volume":"9","author":"Liberini","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2023.175837_bib33","first-page":"S288","article-title":"A review of current guidelines for the treatment of obesity","volume":"28","author":"Marc-Andr\u00e9 Cornier","year":"2022","journal-title":"Am J Manag Care., The Evidence for Semaglutide 2.4 mg in Obesity From a Managed Care Perspective"},{"key":"10.1016\/j.ejphar.2023.175837_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2022.175397","article-title":"Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin","volume":"938","author":"Melander","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.175837_bib35","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2337\/db10-0474","article-title":"Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans","volume":"60","author":"Nauck","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2023.175837_bib36","author":"Novo Nordisk"},{"key":"10.1016\/j.ejphar.2023.175837_bib37","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2023.175837_bib38","series-title":"Potent Anti-obesity Effects of Amylin Analogue ZP8396 in Combination with Semaglutide in DIO Rats","author":"Skarbaliene","year":"2021"},{"key":"10.1016\/j.ejphar.2023.175837_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biomedicines10102365","article-title":"The impact of exposure profile on the efficacy of dual amylin and calcitonin receptor agonist therapy","volume":"10","author":"Sonne","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2023.175837_bib40","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/oby.23371","article-title":"Benefits of weight loss of 10% or more in patients with overweight or obesity: a review","volume":"30","author":"Tahrani","year":"2022","journal-title":"Obesity"},{"key":"10.1016\/j.ejphar.2023.175837_bib41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s13679-020-00422-w","article-title":"Long-term efficacy and safety of anti-obesity treatment: where do we stand?","volume":"10","author":"Tak","year":"2021","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.ejphar.2023.175837_bib42","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1464-5491.2007.02333.x","article-title":"Liraglutide , a once-daily human GLP-1 analogue , improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus","volume":"2","author":"Vilsb\u00f8ll","year":"2008","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ejphar.2023.175837_bib43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0167-0115(03)00111-3","article-title":"Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects","volume":"114","author":"Vilsb\u00f8ll","year":"2003","journal-title":"Regul. Pept."},{"key":"10.1016\/j.ejphar.2023.175837_bib44","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2023.175837_bib45","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"key":"10.1016\/j.ejphar.2023.175837_bib46","first-page":"1","article-title":"Once-Weekly semaglutide in adults with overweight or obesity","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923003485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923003485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:18:15Z","timestamp":1757978295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299923003485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":43,"alternative-id":["S0014299923003485"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175837","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175837","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"175837"}}